Estrella Immunopharma, Inc.
ESLAHealthcare|Biotechnology|US
$0.38
-0.03 (-8.49%)
DCF Value
$0.02
Cash / Share
$0.00
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06343311 T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | P1P2 | Recruiting | 27 | Open-label | EB103 |